ICOTYDE

all catalysts(0)

nothing on the calendar yet

News(4)

• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 6d ago
• 5 biotechs braving the commercial waters with product launches
  A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
  biospace · 18d ago
• J&J touts Icotyde prescriptions, but not sales, in first full quarter
  Johnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…
  endpoints · 2mo ago
• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
  Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
  biopharma_dive · 2mo ago